Mito-LND
Mito-LND (Mito-Lonidamine) is an orally active and mitochondria-targeted inhibitor of oxidative phosphorylation (OXPHOS) . Mito-LND inhibits mitochondrial bioenergetics, stimulates the formation of reactive oxygen species, and induces autophagic cell death in lung cancer cells[1].
Product Specifications
CAS Number
[2361564-49-8]
Product Name Alternative
Mito-Lonidamine
UNSPSC
12352005
Target
Autophagy; Mitochondrial Metabolism; Oxidative Phosphorylation; Reactive Oxygen Species (ROS)
Type
Reference compound
Related Pathways
Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mito-lnd.html
Purity
97.00
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(NCCCCCCCCCC[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3)C4=NN(CC5=CC=C(Cl)C=C5Cl)C6=C4C=CC=C6.[Br-]
Molecular Formula
C43H45BrCl2N3OP
Molecular Weight
801.62
References & Citations
[1]Gang Cheng, et al. Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis. Nat Commun. 2019 May 17;10 (1) :2205.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Lentiviral human AARSD1 sgRNA gene knockout kit - Lentiviral human AARSD1 sgRNA gene knockout kit (100)
WBP1 (WW Domain-binding Protein 1, WBP-1) (MaxLight 405) discontinued
